论文部分内容阅读
目的:观察应用来氟米特联合强的松治疗乙型肝炎病毒相关性肾炎的临床疗效及安全性。方法:对17例经病理确诊的乙型肝炎病毒相关性肾炎患者应用来氟米特联合强的松治疗,治疗前及治疗后检测患者相关指标,并记录不良反应情况。结果:治疗后3个月,24 h尿蛋白定量较前明显减少,连续随访12个月完全缓解11例,总有效率88.2%。结论:来氟米特联合强的松用于治疗乙型肝炎病毒相关性肾炎有明显疗效。
Objective: To observe the clinical efficacy and safety of leflunomide and prednisone in treatment of hepatitis B virus-associated nephritis. Methods: 17 patients with pathologically diagnosed hepatitis B virus associated nephritis were treated with leflunomide combined with prednisone. Before and after treatment, the patients’ relevant indexes were detected and the adverse reactions were recorded. Results: At 3 months after treatment, urinary protein excretion in 24 h was significantly reduced compared with that before treatment. Eleven patients were completely relieved at 12 months of continuous follow-up, with a total effective rate of 88.2%. Conclusion: Leflunomide and prednisone are effective in treating hepatitis B virus-associated nephritis.